FDA grants Fast Track Designation to ... - Advanced Prostate...

Advanced Prostate Cancer

22,277 members27,978 posts

FDA grants Fast Track Designation to ONCT-534 for mCRPC

DrawingSnowmen profile image
4 Replies

urologytimes.com/view/fda-g...

Written by
DrawingSnowmen profile image
DrawingSnowmen
To view profiles and participate in discussions please or .
4 Replies
DrawingSnowmen profile image
DrawingSnowmen

Here's the trial, Nebraska, Texas and Virginia:

clinicaltrials.gov/study/NC...

spencoid2 profile image
spencoid2

this explains what ONCT-534 is I had no idea prior to finding this. is this something to get excited about? i am headed toward Pluvicto kicking and screaming. might this be a better option?

oncternal.com/pipeline/onct...

DrawingSnowmen profile image
DrawingSnowmen in reply tospencoid2

The ONCT-534 isn't available except in the trial and it's a phase 1/2, so it's completely unproven although it looks promising. Pluvicto has clinical trials behind it so if you need it now I would think that would be the more logical choice.

spencoid2 profile image
spencoid2 in reply toDrawingSnowmen

the problem is that i do not know how much i really "need" pluvicto. my PSA is doubling at .9 months but who knows why and if this will continue. i also do not know if the fairly small radiographic progression is something to worry about or not. the PSMA scan might reveal more about how much and where. i can tolerate the bone pain with a little morphine but am worried if that will spread and increase in intensity and how fast. obviously i need to do something but how critical is it that i act quickly? i have an appointment for an opinion from a third oncologist. she is supposed to be very knowledgeable about everything PC related and is not affiliated with UCSF I trust Dr. Aggerwal and do not think he is just pushing a UCSF one size fits all but another opinion can not hurt.

Not what you're looking for?

You may also like...

FDA Fast Track Designation for 225Ac-FL-020 for mCRPCa

Another weapon, from Germany this time....ahhhh zee germanz! Actinium strikes again! Phase 1 trial...
Maxone73 profile image

Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage...
God_Loves_Me profile image

FDA Grants Priority Review to Apalutamide ...

... based on data from the phase III SPARTAN trial (ARN-509-003) News item [1]. Apalutamide may be...
pjoshea13 profile image

Update: FDA grants Priority Review for 177Lu-PSMA-617 for patients with metastatic castration-resistant

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for...
GregHouston profile image